Edwards Lifesciences Other accrued liabilities increased by 1.1% to $179.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 110.8%, from $85.10M to $179.40M. Over 5 years (FY 2020 to FY 2025), Other accrued liabilities shows an upward trend with a 15.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A sudden increase may indicate rising operational overhead or pending settlements, while stability suggests predictable expense management.
This captures miscellaneous short-term obligations that do not fall into specific categories like accounts payable or ac...
Standard across all capital-intensive industries as a residual category for miscellaneous payables.
other_other_accrued_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $82.40M | $88.30M | $87.60M | $88.20M | $78.30M | $78.60M | $80.60M | $83.20M | $81.50M | $80.90M | $89.80M | $100.30M | $82.40M | $88.00M | $96.40M | $85.10M | $85.30M | $104.40M | $177.50M | $179.40M |
| QoQ Change | — | +7.2% | -0.8% | +0.7% | -11.2% | +0.4% | +2.5% | +3.2% | -2.0% | -0.7% | +11.0% | +11.7% | -17.8% | +6.8% | +9.5% | -11.7% | +0.2% | +22.4% | +70.0% | +1.1% |
| YoY Change | — | — | — | — | -5.0% | -11.0% | -8.0% | -5.7% | +4.1% | +2.9% | +11.4% | +20.6% | +1.1% | +8.8% | +7.3% | -15.2% | +3.5% | +18.6% | +84.1% | +110.8% |